Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma

[1] Harousseau JL(2009)The role of complete response in multiple myeloma Blood 114 3139-3146

[2] Attal M(2007)High-dose therapy for multiple myeloma—getting beyond high-dose melphalan Haematologica 92 2-2617

[3] Avet-Loiseau H(2003)A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609-2598

[4] Giralt S(2003)The proteasome—an emerging therapeutic target in cancer N Engl J Med 348 2597-2380

[5] Qazilbash M(2003)The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood 101 2377-37

[6] Richardson PG(2009)A randomized phase I trial of melphalan and bortezomib for autologous transplant in myeloma Clin Lymphoma Myeloma 9 560-390

[7] Barlogie B(2010)Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with Blood 115 32-1473

[8] Berenson J(2006) multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM) Br J Haematol 134 385-undefined

[9] Singhal S(2006)The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study Leukemia 20 1467-undefined

[10] Jagannath S(undefined)International uniform response criteria for multiple myeloma undefined undefined undefined-undefined

[1] Harousseau JL(2009)The role of complete response in multiple myeloma Blood 114 3139-3146

[2] Attal M(2007)High-dose therapy for multiple myeloma—getting beyond high-dose melphalan Haematologica 92 2-2617

[3] Avet-Loiseau H(2003)A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609-2598

[4] Giralt S(2003)The proteasome—an emerging therapeutic target in cancer N Engl J Med 348 2597-2380

[5] Qazilbash M(2003)The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood 101 2377-37

[6] Richardson PG(2009)A randomized phase I trial of melphalan and bortezomib for autologous transplant in myeloma Clin Lymphoma Myeloma 9 560-390

[7] Barlogie B(2010)Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with Blood 115 32-1473

[8] Berenson J(2006) multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM) Br J Haematol 134 385-undefined

[9] Singhal S(2006)The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study Leukemia 20 1467-undefined

[10] Jagannath S(undefined)International uniform response criteria for multiple myeloma undefined undefined undefined-undefined